- Q1. How do I know if I qualify for one of the ORAL trials?
- If you are over 18 and have been diagnosed with rheumatoid arthritis you may be eligible to participate in one of the ORAL trials. Both men and women can participate.
- Q2. How do I enroll in the ORAL trials?
- If you are eligible, you may apply to participate online or contact us by phone at 800-718-1021.
- Q3. How much does it cost to participate in the ORAL trials?
- It does not cost anything to enroll in the ORAL trials. Moreover, if you are eligible, you will receive study-related medical care, including visits with a rheumatologist at no cost.
- Q4. How long will I be enrolled in the ORAL trials?
- If you are eligible, you will participate in one of two ORAL trials, which will last from six to 24 months, depending on the trial. Should you decide to enroll, your study doctor will tell you which of the six trials is best for you, according to your treatment history.
- Q5. How do I know which ORAL trial to enroll in?
- After visiting a study doctor at the site nearest you, he or she will tell you which of the ORAL trials is best for you according to your treatment history. You do not need to choose a trial yourself.
- Q6. What is tasocitinib (CP-690,550)?
- The investigational drug in the ORAL trials is called tasocitinib (CP-690,550) and is being developed as a non-biologic potential DMARD (Disease Modifying Anti-Rheumatic Drug). Learn more about tasocitinib (CP-690,550).
- Q7. How is tasocitinib (CP-690,550) administered?
- Tasocitinib (CP-690,550) is a pill taken by mouth, unlike many current RA treatments which are injected under the skin or infused.
- Q8. Can I get tasocitinib (CP-690,550) without participating in the ORAL trials?
- At this time tasocitinib (CP-690,550) is not currently on the market anywhere in the world. For now, participation in the ORAL trials is the only way to access the investigational drug.
